Xenograft are the cells of one species transplanted to another species.
Acute myeloid leukemia (AML) is a very aggressive disease in which cells proliferate abnormally, invading the bone marrow and interfering with normal blood cell production. It is the most common acute leukemia in adults with the worst prognosis.
A new research paper was published in Oncotarget's Volume 14 on May 26, 2023, entitled, "Deconstructing the role of MALAT1 in MAPK-signaling in melanoma: insights from antisense oligonucleotide treatment."
Research unveils the significance of uridine as a metabolic fuel in pancreatic ductal adenocarcinoma (PDA) cells under glucose-deprived conditions. Uridine utilization, mediated by uridine phosphorylase 1 (UPP1), supports redox balance, survival, and proliferation in PDA, highlighting its potential as a novel therapeutic target in the treatment of this resistant cancer.
Pancreatic cancer is the seventh leading cause of cancer death worldwide and despite the increasing incidence of this disease, effective treatments are lacking and prognosis for patients with this tumor type remains poor, with approximately 70% of patients dying within one year of diagnosis.
Researchers investigated whether functional connectivity between glioblastoma and the brain affected neural circuits.
A new approach to chimeric antigen receptor T-cell (CAR T) therapy has shown great promise against small cell lung cancer (SCLC) in a preclinical study.
A recent study reveals that DCAF1 is overexpressed and phosphorylates EZH2 in colon cancer cells.
As part of the worldwide effort to facilitate a research and clinical pathway toward successful xenotransplantation -; the transplantation of living cells, tissues and organs from one species to another -; two Johns Hopkins Medicine surgeons, Kazuhiko Yamada, M.D., Ph.D., and Andrew Cameron, M.D., Ph.D., will receive a total of $21.4 million in funding over the next two years under two sponsored research agreements with biotechnology company United Therapeutics Corporation.
Decisions on cancer treatment could become better tailored to individual patients with the adoption of a new imaging method being developed by University of Michigan researchers that maps the chemical makeup of a patient’s tumor.
For the past few decades, Dr. Iwao Ojima has been working in his Stony Brook University Department of Chemistry Laboratory and through the Institute of Chemical Biology & Drug Discovery (ICB&DD) to develop next-generation anti-cancer agents.
Researchers demonstrated the use of ants as olfactory bio-detectors of human tumors.
A new research paper was published in Oncotarget's Volume 14 on January 12, 2023, entitled, "Targeting CD74 in B-cell non-Hodgkin lymphoma with the antibody-drug conjugate STRO-001."
A new research paper was published in Genes & Cancer on December 14, 2022, entitled, "Slit2 signaling stimulates Ewing sarcoma growth."
Cooling brain tumor cells to stop them from dividing without killing healthy cells extended the survival of glioblastoma (GBM) animal models dramatically in a study led by a UT Southwestern resident.
The recent years have seen a wave of adoptive cell therapies (ACTs), a type of immunotherapy in which T cells (T cell transfer therapy) and other immune cells are obtained from patients, activated and multiplied outside the body, and infused in larger numbers back into the blood circulation to help fight cancers.
Researchers assessed the efficacy of CAR T-cells in the immunotherapy of colorectal cancer.
A recent study demonstrated a novel method for delivering anti-cancer drugs, conjugated to modified cell-penetrating peptides across the blood-brain barrier, in mice to treat glioblastoma.
A recent study to be presented at the American Heart Association (AHA) Scientific Sessions 2022* revealed unexpected changes in the electrical conduction system of the first genetically-modified porcine-to-human heart xenotransplant.
This study is led by Dr. Longtao Huangfu, and Dr. Xiaoyang Wang (Peking University Cancer Hospital & Institute). A diet of fresh fruits and vegetables may reduce the prevalence of cancers, including GC (Eusebi et al., 2020; Liu et al., 2021).
The Broad Institute of MIT and Harvard, Dana-Farber Cancer Institute and St. Jude Children's Research Hospital today announced the largest academic collaboration of its kind to transform and accelerate the identification of vulnerabilities in pediatric cancers and translate them into better treatments.